KBI Biopharma Executive and Leadership Team

Shardene Basisa, the Chief Executive Officer at KBI Biopharma, directs the overarching strategic vision for the organization. By aligning internal development capabilities with the evolving needs of the biopharmaceutical sector, the Chief Executive Officer ensures the company maintains a competitive edge in complex manufacturing. Shardene Basisa oversees the integration of advanced technologies to streamline drug development cycles, ultimately fostering breakthroughs that improve patient lives globally. This leadership role involves constant collaboration with the Board to secure long-term growth and operational excellence. Through rigorous oversight of corporate initiatives, the Chief Executive Officer drives the mission of delivering high-quality therapeutic solutions. By prioritizing innovation and efficiency, the executive maintains the company's status as a premier CDMO. Shardene Basisa consistently evaluates market trends to pivot resources toward high-impact projects, ensuring the organization remains at the forefront of the industry while delivering consistent value to stakeholders and patients alike.

Katherine Wolf, the Chief Financial Officer at KBI Biopharma, architects the financial strategy necessary to sustain rapid innovation and infrastructure expansion. Overseeing capital allocation, the Chief Financial Officer ensures that investments in new manufacturing technologies align with the company's long-term growth targets. Katherine Wolf manages fiscal planning, risk assessment, and financial reporting to provide the transparency required for strategic decision-making. This leadership role involves close coordination with the executive team to balance operational costs with the need for continuous R&D investment. By optimizing the financial structure, the Chief Financial Officer supports the organization's ability to scale production capabilities for diverse biopharmaceutical clients. Katherine Wolf drives fiscal discipline across all departments, ensuring that resources remain focused on high-impact initiatives. Through rigorous financial oversight, the executive secures the stability required to navigate the competitive CDMO landscape, ultimately enabling the company to deliver consistent value while advancing the development of critical medical treatments for patients worldwide.

Peter Carbone, the Chief Operating Officer at KBI Biopharma, manages the daily execution of complex manufacturing processes across all facilities. Overseeing the technical infrastructure, the Chief Operating Officer ensures that production workflows meet stringent regulatory standards while maximizing output efficiency. Peter Carbone coordinates with site leaders to optimize supply chain logistics and resource allocation, directly supporting the company's goal of accelerating biopharmaceutical development. This role requires constant monitoring of operational metrics to identify bottlenecks and implement scalable solutions. By refining internal processes, the Chief Operating Officer enhances the reliability of manufacturing services provided to global clients. Peter Carbone maintains a focus on operational excellence, ensuring that every project aligns with the broader mission of delivering life-changing therapies. Through the implementation of advanced manufacturing protocols, the executive secures the company's reputation for quality and precision, driving consistent performance across the entire production network while supporting the organization's long-term growth objectives.

Toshihiro Ogawa, the President, Kbi Biopharma (Japan) at KBI Biopharma, directs the expansion and operational success of the company within the Asian market. Overseeing regional initiatives, the President, Kbi Biopharma (Japan) ensures that local manufacturing capabilities meet the specific regulatory and quality standards required for the Japanese biopharmaceutical sector. Toshihiro Ogawa manages local partnerships and client relationships, driving the company's growth strategy in this critical geographic region. This role involves aligning regional operations with the global mission to ensure consistency in service delivery and quality. By leveraging local market insights, the executive identifies opportunities for business development and operational scaling. Toshihiro Ogawa coordinates with the global leadership team to integrate regional performance into the broader corporate strategy. Through the effective management of regional resources, the executive secures the company's footprint in the Asian market, ensuring that the organization continues to provide high-quality manufacturing solutions that positively impact patients across the region.

Shaguna Seth, the Global Project Management Office Head Chief of Staff at KBI Biopharma, directs the synchronization of cross-functional teams to ensure seamless project delivery. Overseeing the project management framework, the Global Project Management Office Head Chief of Staff ensures that complex biopharmaceutical development programs adhere to strict timelines and quality benchmarks. Shaguna Seth facilitates communication between departments, removing operational silos to enhance organizational agility. This role involves managing the strategic alignment of internal resources with client requirements, ensuring that every project contributes to the company's mission of improving patient outcomes. By standardizing project methodologies, the executive increases efficiency across the global portfolio. Shaguna Seth monitors project health and performance metrics, providing the leadership team with actionable insights to drive continuous improvement. Through the coordination of diverse teams, the executive ensures that the company maintains its reputation for excellence in project execution, supporting the successful delivery of innovative therapies to the global market.

Debra Bruneau, the Chief People Officer at KBI Biopharma, architects the human capital strategy to attract and retain top-tier talent in the competitive biopharmaceutical industry. Overseeing organizational culture, the Chief People Officer ensures that the workforce remains aligned with the company's mission of driving breakthroughs in patient care. Debra Bruneau manages talent development, performance management, and employee engagement initiatives to foster a high-performance environment. This leadership role involves collaborating with other executives to build a diverse and inclusive workplace that supports innovation. By implementing robust training programs, the Chief People Officer ensures that the staff possesses the technical expertise required for advanced manufacturing operations. Debra Bruneau drives initiatives that promote professional growth, ensuring that the company remains an employer of choice. Through the cultivation of a strong corporate culture, the executive supports the organization's ability to attract the specialized talent necessary to maintain its position as a leader in the CDMO sector.